Nitric Oxide-mediated Cardioprotection During Cardiac Surgery With Cardiopulmonary Bypass (NOinCPB)
Coronary Artery Disease, Coronary Artery Bypass, Cardiopulmonary Bypass
About this trial
This is an interventional prevention trial for Coronary Artery Disease focused on measuring Cardioprotection, Ischemia-reperfusion injury, Nitric oxide, Cardiopulmonary bypass, Coronary artery bypass grafting
Eligibility Criteria
Inclusion Criteria:
- Coronary artery disease requiring coronary artery bypass grafting with the cardiopulmonary bypass.
Exclusion Criteria:
- Non-elective surgery, age over 70 years, left ventricular ejection fraction less than 35%, history of myocardial infarction within three months prior to surgery, chronic atrial fibrillation, diabetes mellitus, and the elevated levels of cardiac specific markers within 12 h prior to the intervention.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Nitric Oxide
Standard CPB
Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease.
Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.